Adaptive’s high-throughput antibody discovery process enables rapid identification and selection of potent, naturally occurring, entirely human antibodies for clinical development and commercialization.
Neutralizing antibodies defend healthy cells by blocking the biological function of an invading virus.
Adaptive has identified and characterized ultra-potent, neutralizing antibodies that bind to different parts of the SARS-CoV-2 virus and can be considered for development to treat COVID-19.
View Publications for the article published in Cell Chemical Biology in 2023.